

Incorporation of Explicit Arterial Input Function for DCE-MRI Quantification: Use in Human trial of Sorafenib in Renal Cell Carcinoma

M. Rosen¹, K. Flaherty¹, D. Heitjan¹, B. Schwartz², P. O'Dwyer¹

¹University of Pennsylvania, Philadelphia, PA, United States, ²Bayer Pharmaceutical Corp, West Haven, CT, United States

Background: Dynamic contrast-enhanced MRI (DCE-MRI) has been utilized as a means of assessing tumor microvasculature, and has been incorporated into human clinical trials of vascular-targeted therapies (1). Quantification of DCE-MRI tumor enhancement requires an arterial input function (AIF), in order to calculate the serum-tumor 1st order transfer constant, K_{trans}(2). Often, a population-based AIF (3) is assumed. However, this model neglects the 1st pass effect of gadolinium bolus. We demonstrate a semi-automated method for deriving an empiric AIF from DCE-MRI images using an arterial region of interest, ROI and incorporate this function in a clinical trial of DCE-MRI for monitoring tumor therapy.




Figure 1: Arterial gadolinium vs. time curve, and resulting fitted AIF function. The comparison standard bi-exponential (“Weinmann”) function is in red.

Methods: Seventeen patients with locally advanced or metastatic RCC were enrolled in a prospective study of the Raf kinase inhibitor Sorafenib (Bayer, Inc., Hartford, CT). DCE-MRI was performed prior to initiation of therapy, and between day 21 and 72 of therapy to assess for anti-vascular effects on tumors. DCE-MRI was performed on a 1.5T magnet (Symphony©, Siemens, Erlangen, Germany). The study was approved by the local IRB. Arterial ROIs were selected to generate an averaged arterial enhancement curve for each DCE-MRI exam. From these curves, an empiric AIF of the form $AIF = G + L * W$, where G is a gamma variate function, and L*W is a linear washout function modified by a logistic function was generated (Figure 1). This “explicit” AIF was then used as input for the two compartment model to derive whole tumor K_{trans} values. Results were compared to those using the population standard (“Weinmann”) function.

tumor K_{trans} values between the two methods was significant pre-therapy (R=0.65, p=0.005), but not post-therapy R=0.43, p=0.11). Kaplan-Meier survival curves for time to progression were evaluated based on percent change in K_{trans} post therapy either method. Using a cutoff of $\Delta K_{trans} \leq 30\%$, survival was significantly correlated with ΔK_{trans} using explicit AIF method, but not the standard AIF method (Figure 2).

Results: Median K_{trans} values pre-therapy were lower using the explicit AIF (0.93 min⁻¹) than using the Weinmann AIF (1.31 min⁻¹). Post-therapy changes were less pronounced between the two methods (0.44 and 0.47 min⁻¹, respectively). The rank correlation of





Figure 2: Kaplan-Meier curves (progression free survival) using the percent change in tumor K_{trans} as derived with either a population based AIF (left) or the patient-explicit AIF (right). Progression is highly correlated with ΔK_{trans} using explicit AIF (p=0.025), but not population-based AIF (p=0.87).

Conclusion: Use of measured AIFs during DCE-MRI studies can dramatically alter the derived whole tumor K_{trans} values. These values are more likely to be reflective of actual tumor vascular physiology. In a clinical trial of Sorafenib in advanced renal cell carcinoma, the incorporation of individualized AIFs alters the predictive value of percent change of tumor K_{trans} for progression free survival.

References:

1. Morgan, B et al. *J Clin Oncol* 21:3955-64 (2003)
2. Tofts, PS et al. *J Mag Reson Imag* 10:223-32 (1999)
3. Weinmann, et al. *Radiol* 142:619-24 (1984)